From Newborns to Older Adults
UNCOVER THE REALITY OF RSV
DISCOVER WHO IS AT RISK OF SERIOUS COMPLICATIONS
Respiratory syncytial virus (RSV) is a common, highly contagious virus that can compromise the lungs and breathing passages.1
RSV is most severe in young infants and older adults, for whom serious lung infections can lead to hospitalization and may be life-threatening.2,3
Who’s at high risk for severe RSV infection?
Premature infants
and infants (≤ 6 months)4
Children (< 2 years) with
chronic medical conditions4
Older adults
(≥ 60 years)5
People with an immunodeficiency4
People with certain underlying conditions4,5
Such as chronic cardiopulmonary disease
Learn more about who’s at risk for RSV
The impact of RSV
RSV is a highly contagious virus with potentially severe outcomes.
Learn more about the burden of RSV

Learn more about RSV
References :
1. Centers for Disease Control and Prevention (CDC). RSV in infants and young children fact sheet. Updated September 2023. Accessed July 4, 2024. https://www.cdc.gov/rsv/downloads/RSV-in-Infants-and-Young-Children.pdf. 2. Ontario Ministry of Health and Ministry of Long-Term Care. Respiratory syncytial virus (RSV). Accessed July 4, 2024. https://www.health.gov.on.ca/en/pro/programs/drugs/funded_drug/fund_respiratory.aspx. 3. Government of Canada. Respiratory syncytial virus (RSV): for health professionals. Accessed July 4, 2024. https://www.canada.ca/en/public-health/services/diseases/respiratory-syncytial-virus-rsv/health-professionals.html. 4. Centers for Disease Control and Prevention (CDC). RSV in infants and young children. Accessed July 4, 2024. https://www.cdc.gov/rsv/infants-young-children/?CDC_AAref_Val=https://www.cdc.gov/rsv/high-risk/infants-young-children.html. 5. Centers for Disease Control and Prevention (CDC). Older adults are at high risk for severe RSV illness fact sheet. Updated April 2024. Accessed July 4, 2024 https://www.cdc.gov/rsv/factsheet-older-adults.pdf.
This site is intended for Canadian healthcare professionals only.
© 2024 Pfizer Canada ULC, Kirkland, Quebec H9J 2M5 | PP-A1G-CAN-0097-EN
© 2024 Pfizer Canada ULC, Kirkland, Quebec H9J 2M5 PP-A1G-CAN-0097-EN
